Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
74.85
+4.13 (5.84%)
At close: Oct 8, 2025, 4:00 PM EDT
77.00
+2.15 (2.87%)
After-hours: Oct 8, 2025, 6:38 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,999,571
Market Cap
827.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PVLA News
- 14 days ago - Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies - GlobeNewsWire
- 16 days ago - Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM - Seeking Alpha
- 21 days ago - Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy - GlobeNewsWire
- 23 days ago - Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations - GlobeNewsWire
- 5 weeks ago - Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. - GlobeNewsWire
- 5 weeks ago - Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 - GlobeNewsWire